Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Clinical trials of a vaccine designed to trigger the body to attack a protein linked to colon cancer are currently being conducted by scientists at the University of Pittsburgh School of Medicine. The vaccine activates the immune system to target a defective protein which is prevalent in colorectal cancer tissue and other precancerous tissues. Researchers hope, if proven successful, the vaccine may eliminate the need for repeated colon screenings in high-risk patients. These patients tend to have multiple precancerous polyps, called advanced adenomas, in their intestines. Routine colonoscopies look for signs of recurrence of the polyps.

Read the rest of this entry »